Pablo MenÃ©ndez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2094199/publications.pdf

Version: 2024-02-01

233 papers	10,962 citations	30070 54 h-index	39675 94 g-index
265 all docs	265 docs citations	265 times ranked	15401 citing authors

#	Article	IF	Citations
1	A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. Molecular Therapy, 2022, 30, 550-563.	8.2	21
2	The insecticides permethrin and chlorpyrifos show limited genotoxicity and no leukemogenic potential in human and murine hematopoietic stem progenitor cells. Haematologica, 2022, 107, 544-549.	3.5	3
3	Robust In Vitro and In Vivo Immunosuppressive and Anti-inflammatory Properties of Inducible Caspase-9-mediated Apoptotic Mesenchymal Stromal/Stem Cell. Stem Cells Translational Medicine, 2022, 11, 88-96.	3.3	4
4	Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers. Cancer Immunology Research, 2022, 10, 498-511.	3.4	12
5	The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia. Cancers, 2022, 14, 1593.	3.7	1
6	Near-Haploidy and Low-Hypodiploidy in B-Cell Acute Lymphoblastic Leukemia: When Less Is Too Much. Cancers, 2022, 14, 32.	3.7	11
7	Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood highâ€hyperdiploid Bâ€cell acute lymphoblastic leukemia. Molecular Oncology, 2022, 16, 2899-2919.	4.6	5
8	HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia. Leukemia, 2021, 35, 2086-2091.	7.2	8
9	H3K79me2/3 controls enhancerâ€“promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells. Leukemia, 2021, 35, 90-106.	7.2	35
10	Aneuploidy in Cancer: Lessons from Acute Lymphoblastic Leukemia. Trends in Cancer, 2021, 7, 37-47.	7.4	20
11	Enforced sialylâ€Lewisâ€X (sLeX) display in Eâ€selectin ligands by exofucosylation is dispensable for CD19â€CAR Tâ€cell activity and bone marrow homing. Clinical and Translational Medicine, 2021, 11, e280.	4.0	11
12	A Benchmark Side-by-Side Comparison of Two Well-Established Protocols for in vitro Hematopoietic Differentiation From Human Pluripotent Stem Cells. Frontiers in Cell and Developmental Biology, 2021, 9, 636704.	3.7	0
13	Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia. Journal of Clinical Investigation, 2021, 131, .	8.2	14
14	Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Nonâ€“Hodgkin Lymphoma. Clinical Cancer Research, 2021, 27, 6591-6601.	7.0	8
15	MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia. Frontiers in Cell and Developmental Biology, 2021, 9, 695225.	3.7	4
16	Engraftment characterization of risk-stratified AML patients in NSGS mice. Blood Advances, 2021, 5, 4842-4854.	5.2	5
17	KMT2A-CBLrearrangements in acute leukemias: clinical characteristics and genetic breakpoints. Blood Advances, 2021, 5, 5617-5620.	5.2	1
18	Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica, 2020, 105, 1032-1041.	3.5	29

#	Article	IF	Citations
19	In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. Nature Communications, 2020, 11, 5060.	12.8	60
20	Immunotherapy with CAR-T cells in paediatric haematology-oncology. Anales De PediatrÃa (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.2	0
21	CRISPR/Cas9â€“Mediated Gene Knockout and Knockin Human iPSCs. Methods in Molecular Biology, 2020, , 559-574.	0.9	7
22	Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope. , 2020, 8, e000896.		7
23	Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity. , 2020, 8, e001419.		16
24	A NEWral approach for HSC production in vitro?. Blood, 2020, 136, 2845-2847.	1.4	0
25	Impaired Condensin Complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL. Blood, 2020, 136, 313-327.	1.4	16
26	41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. , 2020, 8, e000845.		37
27	Genotoxicity of permethrin and clorpyriphos on human stem and progenitor cells at different ontogeny stages: implications in leukaemia development. EFSA Supporting Publications, 2020, 17, 1866E.	0.7	2
28	Proâ€inflammatory cytokines favor the emergence of ETV6â€RUNX1â€positive preâ€leukemic cells in a model of mesenchymal niche. British Journal of Haematology, 2020, 190, 262-273.	2.5	25
29	Shared D-J rearrangements reveal cell of origin of TCF3-ZNF384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL. Blood, 2020, 136, 1108-1111.	1.4	5
30	Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells. Molecular Therapy - Nucleic Acids, 2020, 20, 196-204.	5.1	12
31	Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML. Genes, 2020, 11, 73.	2.4	2
32	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Haematologica, 2019, 104, 778-788.	3.5	17
33	GATA2 Promotes Hematopoietic Development and Represses Cardiac Differentiation of Human Mesoderm. Stem Cell Reports, 2019, 13, 515-529.	4.8	27
34	Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs. Blood, 2019, 134, 1059-1071.	1.4	62
35	Natural history and cell of origin of TCF3-ZNF384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL. Blood, 2019, 134, 900-905.	1.4	25
36	Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between AF4-MLL and MLL-AF4 fusions. Haematologica, 2019, 104, 1189-1201.	3.5	15

#	Article	IF	Citations
37	Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis. Haematologica, 2019, 104, 1176-1188.	3.5	76
38	Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment. Nucleic Acids Research, 2019, 47, 5016-5037.	14.5	23
39	Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood, 2019, 133, 2291-2304.	1.4	87
40	CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity. Leukemia, 2019, 33, 2090-2125.	7.2	30
41	Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions. Molecular Therapy - Methods and Clinical Development, 2019, 12, 134-144.	4.1	77
42	NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia. Leukemia, 2019, 33, 1557-1569.	7.2	30
43	Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis. Haematologica, 2019, 104, e54-e58.	3.5	12
44	"Identification of Mechanisms By Which Mesenchymal Stem/Stromal Cells Contribute to Acute Myeloid Leukemia". Blood, 2019, 134, 5194-5194.	1.4	0
45	Epigenome-wide analysis reveals specific DNA hypermethylation of T cells during human hematopoietic differentiation. Epigenomics, 2018, 10, 903-923.	2.1	11
46	Detection of inflammatory monocytes but not mesenchymal stem/stromal cells in peripheral blood of patients with myelofibrosis. British Journal of Haematology, 2018, 181, 133-137.	2.5	7
47	The MLL recombinome of acute leukemias in 2017. Leukemia, 2018, 32, 273-284.	7.2	527
48	NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL. Leukemia, 2018, 32, 633-644.	7.2	35
49	CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges. Biomedicines, 2018, 6, 105.	3.2	76
50	Early Human Hemogenic Endothelium Generates Primitive and Definitive Hematopoiesis InÂVitro. Stem Cell Reports, 2018, 11, 1061-1074.	4.8	38
51	IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML. OncoImmunology, 2018, 7, e1477460.	4.6	11
52	Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma. Human Molecular Genetics, 2018, 27, 3046-3059.	2.9	26
53	The â€œNeverâ€Endingâ€•Mouse Models for MLLâ€Rearranged Acute Leukemia Are Still Teaching Us. HemaSphere, 2018, 2, e57.	2.7	8
54	The NOTCH1/CD44 axis drives pathogenesis in a T cell acute lymphoblastic leukemia model. Journal of Clinical Investigation, 2018, 128, 2802-2818.	8.2	48

#	Article	IF	Citations
55	Bone Marrow Mesenchymal Stromal Cells and Inflammation Contribute to ETV6-RUNX1+ Preleukemic Cells Persistence and DNA Damaging. Blood, 2018, 132, 3918-3918.	1.4	0
56	Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Experimental and Molecular Medicine, 2017, 49, e290-e290.	7.7	21
57	Efficient Recreation of t(11;22) EWSR1-FLI1+ in Human Stem Cells UsingÂCRISPR/Cas9. Stem Cell Reports, 2017, 8, 1408-1420.	4.8	52
58	Generation and characterization of a human iPSC cell line expressing inducible Cas9 in the â€œsafe harborâ€•AAVS1 locus. Stem Cell Research, 2017, 21, 137-140.	0.7	26
59	Genetic Rescue of Mitochondrial and Skeletal Muscle Impairment in an Induced Pluripotent Stem Cells Model of Coenzyme Q10 Deficiency. Stem Cells, 2017, 35, 1687-1703.	3.2	24
60	Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research. Archives of Toxicology, 2017, 91, 2763-2780.	4.2	18
61	Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes. Stem Cell Reports, 2017, 8, 1573-1586.	4.8	73
62	Engineered LINE-1 retrotransposition in nondividing human neurons. Genome Research, 2017, 27, 335-348.	5.5	128
63	Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells. Scientific Reports, 2017, 7, 13946.	3.3	34
64	p73 is required for appropriate BMP-induced mesenchymal-to-epithelial transition during somatic cell reprogramming. Cell Death and Disease, 2017, 8, e3034-e3034.	6.3	16
65	DNA methylation changes in human lung epithelia cells exposed to multi-walled carbon nanotubes. Nanotoxicology, 2017, 11, 857-870.	3.0	36
66	RUNX1cRegulates Hematopoietic Differentiation of Human Pluripotent Stem Cells Possibly in Cooperation with Proinflammatory Signaling. Stem Cells, 2017, 35, 2253-2266.	3.2	17
67	Hoxa9 and EGFP reporter expression in human Embryonic Stem Cells (hESC) as useful tools for studying human development. Stem Cell Research, 2017, 25, 286-290.	0.7	7
68	Autogenous Control of 5â€²TOP mRNA Stability by 40S Ribosomes. Molecular Cell, 2017, 67, 55-70.e4.	9.7	78
69	Proinflammatory signals are insufficient to drive definitive hematopoietic specification of human HSCs inÂvitro. Experimental Hematology, 2017, 45, 85-93.e2.	0.4	11
70	Generation, genome edition and characterization of iPSC lines from a patient with coenzyme Q 10 deficiency harboring a heterozygous mutation in COQ4 gene. Stem Cell Research, 2017, 24, 144-147.	0.7	13
71	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemiaâ€“Microenvironment Interactions in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 1493-1505.	7.0	38
72	Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson's disease and childhood leukaemiaâ€. EFSA Journal, 2017, 15, e04691.	1.8	20

#	Article	IF	Citations
73	Human acute leukemia induced pluripotent stem cells: a unique model for investigating disease development and pathogenesis. Stem Cell Investigation, 2017, 4, 55-55.	3.0	3
74	The AF4-MLL fusion transiently augments multilineage hematopoietic engraftment but is not sufficient to initiate leukemia in cord blood CD34+ cells. Oncotarget, 2017, 8, 81936-81941.	1.8	13
75	Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors. Oncotarget, 2017, 8, 66742-66746.	1.8	12
76	Abstract 2169: Pharmacological modulation of CXCL12-CXCR4 intracellular trafficking potentiates thein vitroandin vivoactivity of the BET bromodomain inhibitor CPI203 in diffuse large B-cell lymphoma. , 2017, , .		0
77	Modeling mixed-lineage-rearranged leukemia initiation in CD34 ⁺ cells: a â€œCRISPRâ€• solution. Haematologica, 2017, 102, 1467-1468.	3.5	1
78	Linking Pesticide Exposure with Pediatric Leukemia: Potential Underlying Mechanisms. International Journal of Molecular Sciences, 2016, 17, 461.	4.1	68
79	Cellular Ontogeny and Hierarchy Influence the Reprogramming Efficiency of Human B Cells into Induced Pluripotent Stem Cells. Stem Cells, 2016, 34, 581-587.	3.2	18
80	Intra-Bone Marrow Transplantation Confers Superior Multilineage Engraftment of Murine Aorta-Gonad Mesonephros Cells Over Intravenous Transplantation. Stem Cells and Development, 2016, 25, 259-265.	2.1	10
81	Proinflammatory signaling seems dispensable for hematopoietic specification from human pluripotent stem cells. Experimental Hematology, 2016, 44, S89.	0.4	0
82	RUNX1C regulates hematopoietic specification of human embryonic stem cells. Experimental Hematology, 2016, 44, S89.	0.4	0
83	Candidate biomarkers of transformed mesenchymal stromal/stem cells by quantitative proteomics and glycoproteomics. Experimental Hematology, 2016, 44, S86-S87.	0.4	0
84	Developmental refractoriness of MLL-rearranged human acute B-cell leukemias. Experimental Hematology, 2016, 44, S40.	0.4	0
85	Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency. Stem Cell Reports, 2016, 7, 602-618.	4.8	38
86	Generation of Quantitative Proteomic and Glycoproteomic Profiles Specific to Transformed Mesenchymal Stem Cells. Cytotherapy, 2016, 18, S24.	0.7	0
87	Human embryonic stem cell-derived mesenchymal stromal cells ameliorate collagen-induced arthritis by inducing host-derived indoleamine 2,3 dioxygenase. Arthritis Research and Therapy, 2016, 18, 77.	3.5	39
88	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	3.5	67
89	Activated KRAS Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia. Cancer Research, 2016, 76, 2478-2489.	0.9	37
90	Immunophenotypic analysis and quantification of B-1 and B-2 B cells during human fetal hematopoietic development. Leukemia, 2016, 30, 1603-1606.	7.2	18

#	Article	IF	Citations
91	Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C/EBPÎ±. Leukemia, 2016, 30, 674-682.	7.2	36
92	Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair. Oncotarget, 2016, 7, 30440-30452.	1.8	19
93	Unraveling the mechanisms underlying the refractoriness of MLL-rearranged acute B-cell leukemias to reprogramming into pluripotency. Experimental Hematology, 2015, 43, S54.	0.4	0
94	Reprogramming primary human mature B-cells into induced pluripotent stem cells. Experimental Hematology, 2015, 43, S80.	0.4	0
95	Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood, 2015, 126, 2676-2685.	1.4	100
96	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	2.9	40
97	Concise Review: Induced Pluripotency by Defined Factors: Prey of Oxidative Stress. Stem Cells, 2015, 33, 1371-1376.	3.2	16
98	NF-Î²B activation impairs somatic cell reprogramming in ageing. Nature Cell Biology, 2015, 17, 1004-1013.	10.3	91
99	Bone microenvironment signals in osteosarcoma development. Cellular and Molecular Life Sciences, 2015, 72, 3097-3113.	5.4	147
100	Effectiveness of Efferent Loop Stimulation. Diseases of the Colon and Rectum, 2015, 58, e54-e55.	1.3	0
101	The Notch ligand DLL4 specifically marks human hematoendothelial progenitors and regulates their hematopoietic fate. Leukemia, 2015, 29, 1741-1753.	7.2	48
102	Abdominal strength in voiding cystometry: a risk factor for recurrent urinary tract infections in women. International Urogynecology Journal, 2015, 26, 1861-1865.	1.4	5
103	Activated KRAS enhances extramedullar engraftment and impairs clonogenic potential of MLLAF4-expressing cord blood CD34+ HSPCs but is not sufficient to initiate leukemia. Experimental Hematology, 2015, 43, S89.	0.4	0
104	SCL/TAL1-mediated Transcriptional Network Enhances Megakaryocytic Specification of Human Embryonic Stem Cells. Molecular Therapy, 2015, 23, 158-170.	8.2	25
105	Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking. Cell Death and Differentiation, 2015, 22, 96-107.	11.2	17
106	H3K4me1 marks DNA regions hypomethylated during aging in human stem and differentiated cells. Genome Research, 2015, 25, 27-40.	5.5	119
107	V-Myc Immortalizes Human Neural Stem Cells in the Absence of Pluripotency-Associated Traits. PLoS ONE, 2015, 10, e0118499.	2.5	6
108	Role of BRD4 in hematopoietic differentiation of embryonic stem cells. Epigenetics, 2014, 9, 566-578.	2.7	16

#	Article	IF	Citations
109	Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia. Cell Death and Disease, 2014, 5, e992-e992.	6.3	56
110	Fast and Efficient Neural Conversion of Human Hematopoietic Cells. Stem Cell Reports, 2014, 3, 1118-1131.	4.8	33
111	Bone Environment is Essential for Osteosarcoma Development from Transformed Mesenchymal Stem Cells. Stem Cells, 2014, 32, 1136-1148.	3.2	89
112	HOXA9 promotes hematopoietic commitment of human embryonic stem cells. Blood, 2014, 124, 3065-3075.	1.4	85
113	Inactivation of p53 in Human Keratinocytes Leads to Squamous Differentiation and Shedding via Replication Stress and Mitotic Slippage. Cell Reports, 2014, 9, 1349-1360.	6.4	48
114	Identification of Cdca7 as a novel Notch transcriptional target involved in hematopoietic stem cell emergence. Journal of Experimental Medicine, 2014, 211, 2411-2423.	8.5	46
115	Human Bone Marrow Stromal Cells Lose Immunosuppressive and Anti-inflammatory Properties upon Oncogenic Transformation. Stem Cell Reports, 2014, 3, 606-619.	4.8	33
116	Concise Review: Generation of Neurons From Somatic Cells of Healthy Individuals and Neurological Patients Through Induced Pluripotency or Direct Conversion. Stem Cells, 2014, 32, 2811-2817.	3.2	38
117	RUNX1c regulates hematopoietic specification of human embryonic stem cells. Experimental Hematology, 2014, 42, S16.	0.4	0
118	Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells. Leukemia, 2014, 28, 666-674.	7.2	27
119	Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease. Haematologica, 2014, 99, 1168-1175.	3.5	36
120	Unravelling the Mirnome of MLL-Rearranged Acute Lymphoblastic Leukemia. Blood, 2014, 124, 878-878.	1.4	1
121	Identification of Cdca7 as a novel Notch transcriptional target involved in hematopoietic stem cell emergence. Journal of Cell Biology, 2014, 207, 2074OIA213.	5.2	0
122	Prognostic implications of serum microRNA-21 in colorectal cancer. Journal of Surgical Oncology, 2013, 108, 369-373.	1.7	72
123	The Globoseries Glycosphingolipid SSEA-4 Is a Marker of Bone Marrow-Derived Clonal Multipotent Stromal Cells In Vitro and In Vivo. Stem Cells and Development, 2013, 22, 1387-1397.	2.1	20
124	Effectiveness of Afferent Loop Stimulation Prior to Ileostomy Closure. CirugÃa EspaÃ±ola (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.1	2
125	The MLL recombinome of acute leukemias in 2013. Leukemia, 2013, 27, 2165-2176.	7.2	393
126	Is the Claiming of Costs Justifiable in Jehovah's Witness Surgical Patients After Healthcare That is not Part of the Public Health System?. CirugÃa EspaÃ±ola (English Edition), 2013, 91, 287-293.	0.1	1

#	Article	IF	Citations
127	Implications of the histological determination of microRNAs in the screening, diagnosis and prognosis of colorectal cancer. Journal of Surgical Oncology, 2013, 108, 70-73.	1.7	11
128	Diagnostic and prognostic significance of serum MicroRNAs in colorectal cancer. Journal of Surgical Oncology, 2013, 107, 217-220.	1.7	28
129	Extra-Articular Lateral Tenodesis for Anterior Cruciate Ligament Deficient Knee: A Case Report. Case Reports in Orthopedics, 2013, 2013, 1-5.	0.3	2
130	The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development. Oncogene, 2013, 32, 4970-4980.	5.9	79
131	Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation. Stem Cells, 2013, 31, 2061-2072.	3.2	59
132	The role of RUNX1 isoforms in hematopoietic commitment of human pluripotent stem cells. Blood, 2013, 121, 5250-5252.	1.4	16
133	FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs. Blood, 2013, 121, 3867-3878.	1.4	33
134	Cord blood-derived CD34+ hematopoietic cells with low mitochondrial mass are enriched in hematopoietic repopulating stem cell function. Haematologica, 2013, 98, 1022-1029.	3.5	72
135	Krukenberg tumor after gastric bypass for morbid obesity: Bariatric surgery and gastric cancer. Revista Espanola De Enfermedades Digestivas, 2013, 105, 296-298.	0.3	10
136	A promoter DNA demethylation landscape of human hematopoietic differentiation. Nucleic Acids Research, 2012, 40, 116-131.	14.5	97
137	A human ESC model for MLL-AF4 leukemic fusion gene reveals an impaired early hematopoietic-endothelial specification. Cell Research, 2012, 22, 986-1002.	12.0	49
138	Primary Neuroendocrine Breast Carcinoma. Clinical Breast Cancer, 2012, 12, 300-303.	2.4	14
139	Intrahepatic transplantation of cord blood CD34+ cells into newborn NOD/SCID-IL2RÎ³null mice allows efficient multi-organ and multi-lineage hematopoietic engraftment without accessory cells. Clinical Immunology, 2012, 145, 89-91.	3.2	10
140	Maintenance of Human Embryonic Stem Cells in Mesenchymal Stem Cell-Conditioned Media Augments Hematopoietic Specification. Stem Cells and Development, 2012, 21, 1549-1558.	2.1	27
141	Maintenance of Human Embryonic Stem Cells in Media Conditioned by Human Mesenchymal Stem Cells Obviates the Requirement of Exogenous Basic Fibroblast Growth Factor Supplementation. Tissue Engineering - Part C: Methods, 2012, 18, 387-396.	2.1	20
142	SCL/TAL1 Regulates Hematopoietic Specification From Human Embryonic Stem Cells. Molecular Therapy, 2012, 20, 1443-1453.	8.2	59
143	iPSCs from cancer cells: challenges and opportunities. Trends in Molecular Medicine, 2012, 18, 245-247.	6.7	65
144	Only in patients with hormoneâ€dependent breast infiltrating ductal carcinomas, CA15.3 serum levels are inversely correlated with the immunohistochemical expression of Bcl2. Clinica Chimica Acta, 2012, 413, 1792-1795.	1.1	1

#	Article	IF	Citations
145	Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Research, 2012, 22, 62-77.	12.0	125
146	Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia. Leukemia, 2012, 26, 2360-2366.	7.2	55
147	The Adaptation of Human Embryonic Stem Cells to Different Feeder-Free Culture Conditions Is Accompanied by a Mitochondrial Response. Stem Cells and Development, 2012, 21, 1145-1155.	2.1	25
148	Purification and Long-Term Expansion of Multipotent Endothelial-Like Cells with Potential Cardiovascular Regeneration. Stem Cells and Development, 2012, 21, 562-574.	2.1	37
149	Residual Expression of the Reprogramming Factors Prevents Differentiation of iPSC Generated from Human Fibroblasts and Cord Blood CD34+ Progenitors. PLoS ONE, 2012, 7, e35824.	2.5	61
150	Identification of a Candidate Proteomic Signature to Discriminate Multipotent and Non-Multipotent Stromal Cells. PLoS ONE, 2012, 7, e38954.	2.5	9
151	Specific Marking of hESCs-Derived Hematopoietic Lineage by WAS-Promoter Driven Lentiviral Vectors. PLoS ONE, 2012, 7, e39091.	2.5	13
152	Multipotent Mesenchymal Stromal Cells: Clinical Applications and Cancer Modeling. Advances in Experimental Medicine and Biology, 2012, 741, 187-205.	1.6	32
153	Biological Impact of Human Embryonic Stem Cells. Advances in Experimental Medicine and Biology, 2012, 741, 217-230.	1.6	1
154	Analysis of mRNA Abundance and Stability by Ribonuclease Protection Assay. Methods in Molecular Biology, 2012, 809, 491-503.	0.9	1
155	Does bariatric surgery decrease gastric cancer risk?. Hepato-Gastroenterology, 2012, 59, 409-12.	0.5	10
156	The Nodal inhibitor Lefty is negatively modulated by the microRNA miRâ€302 in human embryonic stem cells. FASEB Journal, 2011, 25, 1497-1508.	0.5	93
157	Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. Blood, 2011, 117, 4746-4758.	1.4	84
158	Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement. Leukemia, 2011, 25, 400-410.	7.2	65
159	Penetrating carotid artery: uncommon complex and lethal injuries. European Journal of Trauma and Emergency Surgery, 2011, 37, 429-437.	1.7	14
160	Subclavian vessel injuries: difficult anatomy and difficult territory. European Journal of Trauma and Emergency Surgery, 2011, 37, 439-449.	1.7	10
161	Enrichment of Human ESC-Derived Multipotent Mesenchymal Stem Cells with Immunosuppressive and Anti-Inflammatory Properties Capable to Protect Against Experimental Inflammatory Bowel Disease. Stem Cells, 2011, 29, 251-262.	3.2	119
162	FUS-CHOP Fusion Protein Expression Coupled to p53 Deficiency Induces Liposarcoma in Mouse but Not in Human Adipose-Derived Mesenchymal Stem/Stromal Cells. Stem Cells, 2011, 29, 179-192.	3.2	57

#	Article	IF	Citations
163	Expression of NG2 antigen in MLL-rearranged acute leukemias: How complex does it get?. Leukemia Research, 2011, 35, 989-990.	0.8	11
164	Large-scale transcriptional profiling and functional assays reveal important roles for Rho-GTPase signalling and SCL during haematopoietic differentiation of human embryonic stem cells. Human Molecular Genetics, 2011, 20, 4932-4946.	2.9	16
165	Is the Centralized Treatment of Small Cell Carcinoma of Anal Canal Necessary? A Case Report. Journal of Cancer Science & Therapy, 2011, 03, .	1.7	0
166	Biological behavior due to cell proliferation markers of gastrointestinal stromal tumors. Hepato-Gastroenterology, 2011, 58, 76-80.	0.5	2
167	Recidiva de linfangiomas quÃsticos retroperitoneales con dificultad para la exÃ©resis quirÃºrgica. Â¿Existen otras alternativas terapÃ©uticas?. Actas UrolÃ³gicas EspaÃ±olas, 2010, 34, 825-826.	0.7	0
168	The ROCK Inhibitor Y-27632 Negatively Affects the Expansion/Survival of Both Fresh and Cryopreserved Cord Blood-Derived CD34+ Hematopoietic Progenitor Cells. Stem Cell Reviews and Reports, 2010, 6, 215-223.	5.6	43
169	Endoplasmic Reticulum Stress Signals in Defined Human Embryonic Stem Cell Lines and Culture Conditions. Stem Cell Reviews and Reports, 2010, 6, 462-472.	5.6	16
170	Human Induced Pluripotent Stem Cells Develop Teratoma More Efficiently and Faster Than Human Embryonic Stem Cells Regardless the Site of Injection. Stem Cells, 2010, 28, 1568-1570.	3.2	281
171	Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells. Nature, 2010, 466, 769-773.	27.8	157
172	Deficiency in p53 but not Retinoblastoma Induces the Transformation of Mesenchymal Stem Cells In vitro and Initiates Leiomyosarcoma In vivo. Cancer Research, 2010, 70, 4185-4194.	0.9	96
173	Nodal/Activin Signaling Predicts Human Pluripotent Stem Cell Lines Prone to Differentiate Toward the Hematopoietic Lineage. Molecular Therapy, 2010, 18, 2173-2181.	8.2	56
174	iPSC lines that do not silence the expression of the ectopic reprogramming factors may display enhanced propensity to genomic instability. Cell Research, 2010, 20, 1092-1095.	12.0	52
175	Intra-bone marrow transplantation of human CD34+ cells into NOD/LtSz-scid IL-2rÎ³null mice permits multilineage engraftment without previous irradiation. Cytotherapy, 2010, 12, 45-49.	0.7	32
176	Lesiones vasculares del cuello. Angiologia, 2010, 62, 150-156.	0.0	0
177	Mesenchymal stem cells facilitate the derivation of human embryonic stem cells from cryopreserved poor-quality embryos. Human Reproduction, 2009, 24, 1844-1851.	0.9	44
178	The miR-302-367 cluster as a potential stemness regulator in ESCs. Cell Cycle, 2009, 8, 394-398.	2.6	156
179	Etoposide induces MLL rearrangements and other chromosomal abnormalities in human embryonic stem cells. Carcinogenesis, 2009, 30, 1628-1637.	2.8	64
180	The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features. Breast Cancer Research and Treatment, 2009, 118, 655-660.	2.5	32

#	Article	IF	Citations
181	Feeder-free maintenance of hESCs in mesenchymal stem cell-conditioned media: distinct requirements for TGF-Î² and IGF-II. Cell Research, 2009, 19, 698-709.	12.0	69
182	Genetic stability of human embryonic stem cells: A first-step toward the development of potential hESC-based systems for modeling childhood leukemia. Leukemia Research, 2009, 33, 980-990.	0.8	32
183	Tumor control and normal tissue complications in BNCT treatment of nodular melanoma: A search for predictive quantities. Applied Radiation and Isotopes, 2009, 67, S153-S156.	1.5	10
184	Dynamic infrared imaging of cutaneous melanoma and normal skin in patients treated with BNCT. Applied Radiation and Isotopes, 2009, 67, S54-S58.	1.5	60
185	Reproductive medicine meets human embryonic stem cell (hESC) research: the need to adjust the regulatory framework to actual expectations and potential detrimental consequences of hESC research. Fertility and Sterility, 2009, 91, 1417-1419.	1.0	1
186	Loss of p53 Induces Tumorigenesis in p21-Deficient Mesenchymal Stem Cells. Neoplasia, 2009, 11, 397-IN9.	5.3	89
187	Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. Journal of Experimental Medicine, 2009, 206, 3131-3141.	8.5	109
188	Electron Microscopy Reveals the Presence of Viruses in Mouse Embryonic Fibroblasts But Neither in Human Embryonic Fibroblasts Nor in Human Mesenchymal Cells Used for hESC Maintenance: Toward an Implementation of Microbiological Quality Assurance Program in Stem Cell Banks. Cloning and Stem Cells, 2008, 10, 65-74.	2.6	41
189	OP9 Stroma Augments Survival of Hematopoietic Precursors and Progenitors During Hematopoietic Differentiation from Human Embryonic Stem Cells. Stem Cells, 2008, 26, 2485-2495.	3.2	54
190	NG2 antigen is expressed in CD34+ HPCs and plasmacytoid dendritic cell precursors: is NG2 expression in leukemia dependent on the target cell where leukemogenesis is triggered?. Leukemia, 2008, 22, 1475-1478.	7.2	37
191	Molecular profiling of candidate human hematopoietic stem cells derived from human embryonic stem cells. Experimental Hematology, 2008, 36, 1436-1448.	0.4	11
192	Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. Journal of Cellular and Molecular Medicine, 2008, 12, 2552-2565.	3.6	129
193	Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties?. Molecular Cancer, 2008, 7, 76.	19.2	143
194	Embryonic Stem Cell-Specific miR302-367 Cluster: Human Gene Structure and Functional Characterization of Its Core Promoter. Molecular and Cellular Biology, 2008, 28, 6609-6619.	2.3	204
195	Whole-Blastocyst Culture Followed by Laser Drilling Technology Enhances the Efficiency of ICM Isolation and ESC Derivation from Good- and Poor-Quality Mouse Embryos: New Insights for Derivation of hESC Lines. Stem Cells and Development, 2008, 17, 255-268.	2.1	24
196	Making business out of patients?. Blood, 2008, 112, 1543-1543.	1.4	0
197	Cancer Genes Hypermethylated in Human Embryonic Stem Cells. PLoS ONE, 2008, 3, e3294.	2.5	75
198	Spanish Stem Cell Bank Interviews Examine the Interest of Couples in Donating Surplus Human IVF Embryos for Stem Cell Research. Cell Stem Cell, 2007, 1, 17-20.	11.1	12

#	Article	IF	Citations
199	Bone marrow stromal cell-derived Wnt signals as a potential underlying mechanism for cyclin D1 deregulation in multiple myeloma lacking t(11;14)(q13;q32). Blood Cells, Molecules, and Diseases, 2007, 39, 366-368.	1.4	9
200	Human embryonic stem cells: A potential system for modeling infant leukemia harboring MLL-AF4 fusion gene. Drug Discovery Today: Disease Models, 2007, 4, 53-60.	1.2	11
201	IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature, 2007, 448, 1015-1021.	27.8	552
202	Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis. Experimental Hematology, 2007, 35, 1477-1478.	0.4	5
203	Evaluation of a laser technique to isolate the inner cell mass of murine blastocysts. Biotechnology and Applied Biochemistry, 2007, 46, 205.	3.1	8
204	Conventional and molecular cytogenetic diagnostic methods in stem cell research: A concise review. Cell Biology International, 2007, 31, 861-869.	3.0	46
205	Human embryonic stem cells: a journey beyond cell replacement therapies. Cytotherapy, 2006, 8, 530-541.	0.7	60
206	Derivation and Characterization of Hematopoietic Cells From Human Embryonic Stem Cells. , 2006, 331, 179-200.		13
207	Clonal isolation of hESCs reveals heterogeneity within the pluripotent stem cell compartment. Nature Methods, 2006, 3, 807-815.	19.0	155
208	Triterpenoids andÂellagic acid derivatives from inÂvitro cultures ofÂCamptothecaÂacuminata Decaisne. Plant Physiology and Biochemistry, 2006, 44, 220-225.	5.8	24
209	Retroviral Transduction of Hematopoietic Progenitors Derived From Human Embryonic Stem Cells. , 2006, 331, 201-220.		1
210	Human embryonic stem cells maintained in the absence of mouse embryonic fibroblasts or conditioned media are capable of hematopoietic development. Blood, 2005, 105, 4598-4603.	1.4	165
211	Human Embryonic Stem Cells: Potential Tool for Achieving Immunotolerance?. Stem Cell Reviews and Reports, 2005, 1, 151-158.	5.6	56
212	Hematopoietic development from human embryonic stem cell lines. Experimental Hematology, 2005, 33, 987-996.	0.4	68
213	Intraâ€“bone marrow transplantation facilitates pauci-clonal human hematopoietic repopulation of NOD/SCID/Î²2mâ^'/â^' mice. Experimental Hematology, 2005, 33, 1417-1426.	0.4	19
214	Genetic Manipulation of Human Embryonic Stem Cells: A System to Study Early Human Development and Potential Therapeutic Applications. Current Gene Therapy, 2005, 5, 375-385.	2.0	69
215	Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. Journal of Experimental Medicine, 2005, 201, 1603-1614.	8.5	290
216	Retroviral transduction of hematopoietic cells differentiated from human embryonic stem cell-derived CD45negPFV hemogenic precursors. Molecular Therapy, 2004, 10, 1109-1120.	8.2	49

#	Article	IF	Citations
217	Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia, 2004, 18, 491-498.	7.2	54
218	First BNCT treatment of a skin melanoma in Argentina: dosimetric analysis and clinical outcome. Applied Radiation and Isotopes, 2004, 61, 1101-1105.	1.5	128
219	Endothelial and Hematopoietic Cell Fate of Human Embryonic Stem Cells Originates from Primitive Endothelium with Hemangioblastic Properties. Immunity, 2004, 21, 31-41.	14.3	353
220	Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy. Leukemia, 2003, 17, 437-441.	7.2	19
221	Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood, 2003, 102, 906-915.	1.4	563
222	A new cytometric method for the immunophenotypic characterization of bone-derived human osteoclasts. Cytometry, 2002, 50, 261-266.	1.8	7
223	The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilizationâ€ƒregimen. Transfusion, 2002, 42, 1159-1172.	1.6	37
224	Influence of the different CD34+ and CD34- cell subsets infused on clinical outcome after non-myeloablative allogeneic peripheral blood transplantation from human leucocyte antigen-identical sibling donors. British Journal of Haematology, 2002, 119, 135-143.	2.5	26
225	Evaluation of a CD61 MoAb method for enumeration of platelets in thrombocytopenic patients and its impact on the transfusion decision-making process. Transfusion, 2001, 41, 1212-1216.	1.6	17
226	Sequential analysis of CD34+ and CD34â˜’ cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide. Leukemia, 2001, 15, 430-439.	7.2	27
227	Immunophenotypic characteristics of PB-mobilised CD34+ hematopoietic progenitor cells. Journal of Biological Regulators and Homeostatic Agents, 2001, 15, 53-61.	0.7	12
228	Different Patterns of Renal Osteodystrophy in Iberoamerica. American Journal of the Medical Sciences, 2000, 320, 76-80.	1.1	24
229	Loss of CD34+ hematopoietic progenitor cells due to washing can be reduced by the use of fixative-free erythrocyte lysing reagents. Journal of Immunological Methods, 2000, 239, 13-23.	1.4	44
230	Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. Journal of Immunological Methods, 2000, 242, 53-65.	1.4	51
231	Comparison between a lyse-and-then-wash method and a lyse-non-wash technique for the enumeration of CD34+ hematopoietic progenitor cells. , 1998, 34, 264-271.		39
232	Fine Needle Aspiration of Sclerosing Lymphocytic Lobulitis of the Breast. Acta Cytologica, 1998, 42, 1447-1450.	1.3	8
233	Staining of bone aluminium: comparison between aluminon and solocbrome azurine and their correlation with bone aluminium content. Nephrology Dialysis Transplantation, 1996, 11, 80-85.	0.7	23